Including 64 KEGG pathways in ASD, 26 in ID, 17 in EE and 34 in SCZ. |
KEGG accession | KEGG pathway name | Number of reference genes | Number of genes | Expected number | Ratio of entrichment | Raw P_Value | Adjusted P_Value | Genes related | Other disease |
---|---|---|---|---|---|---|---|---|---|
04810 | Regulation of actin cytoskeleton | 213 | 13 | 1.63 | 7.98 | 1.27e-08 | 1.23e-06 | SCZ | |
ABI2 | PAK2 | PIK3R2 | ITGB3 | FGD3 | PDGFD | ITGA5 | MYH9 | ROCK1 | NCKAP1 | MYH10 | CHRM3 | |||||||||
04510 | Focal adhesion | 200 | 12 | 1.53 | 7.84 | 5.59e-08 | 2.71e-06 | EE SCZ | |
PTEN | PAK2 | PIK3R2 | ITGB3 | PDGFD | ITGA5 | LAMC3 | RELN | ROCK1 | THBS3 | PRKCA | |||||||||
04972 | Pancreatic secretion | 101 | 8 | 0.77 | 10.35 | 1.18e-06 | 3.82e-05 | EE | |
GNAS | AMY2B | ADCY5 | ITPR1 | KCNMA1 | SLC4A2 | PRKCA | |||||||||
04971 | Gastric acid secretion | 74 | 7 | 0.57 | 12.36 | 1.67e-06 | 4.05e-05 | SCZ | |
GNAS | SLC4A2 | PRKCA | ADCY5 | ITPR1 | CHRM3 | |||||||||
04270 | Vascular smooth muscle contraction | 116 | 8 | 0.89 | 9.01 | 3.35e-06 | 6.50e-05 | SCZ | |
GNAS | ADCY5 | ITPR1 | KCNMA1 | CACNA1S | ROCK1 | CACNA1D | |||||||||
04970 | Salivary secretion | 89 | 7 | 0.68 | 10.28 | 5.80e-06 | 6.75e-05 | EE SCZ | |
GNAS | SLC4A2 | PRKCA | ADCY5 | ITPR1 | KCNMA1 | |||||||||
05010 | Alzheimer's disease | 167 | 9 | 1.28 | 7.04 | 6.26e-06 | 6.75e-05 | ID | |
APH1A | ITPR1 | LRP1 | CACNA1S | CACNA1D | APAF1 | PSEN1 | SDHA | |||||||||
05414 | Dilated cardiomyopathy | 90 | 7 | 0.69 | 10.16 | 6.25e-06 | 6.75e-05 | EE SCZ | |
GNAS | ITGA5 | CACNA1D | CACNA1S | CACNA2D3 | ADCY5 | |||||||||
04512 | ECM-receptor interaction | 85 | 7 | 0.65 | 10.76 | 4.27e-06 | 6.75e-05 | SCZ | |
ITGA5 | LAMC3 | RELN | SV2B | THBS3 | ITGB3 | |||||||||
04020 | Calcium signaling pathway | 177 | 9 | 1.35 | 6.65 | 1.00e-05 | 9.70e-05 | EE SCZ | |
GNAS | CACNA1E | PLCD4 | ITPR1 | CACNA1S | CACNA1D | PRKCA | HRH2 | |||||||||
04912 | GnRH signaling pathway | 101 | 7 | 0.77 | 9.06 | 1.34e-05 | 0.0001 | ID SCZ | |
GNAS | MAPK13 | CACNA1D | CACNA1S | PRKCA | ADCY5 | |||||||||
04070 | Phosphatidylinositol signaling system | 78 | 6 | 0.60 | 10.05 | 3.10e-05 | 0.0002 | - | |
PRKCA | PTEN | PLCD4 | ITPR1 | PIK3R2 | |||||||||
05412 | Arrhythmogenic right ventricular cardiomyopathy (ARVC) | 74 | 6 | 0.57 | 10.60 | 2.29e-05 | 0.0002 | ID SCZ | |
ITGA5 | TCF7L1 | CACNA1D | CACNA1S | CACNA2D3 | |||||||||
04540 | Gap junction | 90 | 6 | 0.69 | 8.71 | 6.96e-05 | 0.0005 | SCZ | |
PDGFD | GNAS | TUBA1A | PRKCA | ADCY5 | |||||||||
04145 | Phagosome | 153 | 7 | 1.17 | 5.98 | 0.0002 | 0.0012 | - | |
ITGA5 | C3 | COLEC12 | THBS3 | TUBA1A | SFTPD | |||||||||
04010 | MAPK signaling pathway | 268 | 9 | 2.05 | 4.39 | 0.0002 | 0.0012 | - | |
CACNA1E | PAK2 | MAPK13 | CACNA1S | CACNA1D | PRKCA | CACNA2D3 | RPS6KA3 | |||||||||
04360 | Axon guidance | 129 | 6 | 0.99 | 6.08 | 0.0005 | 0.0023 | - | |
ROCK1 | EPHB2 | NTNG1 | PAK2 | PLXNB1 | |||||||||
04973 | Carbohydrate digestion and absorption | 44 | 4 | 0.34 | 11.88 | 0.0004 | 0.0023 | - | |
CACNA1D | AMY2B | SLC5A1 | |||||||||
05222 | Small cell lung cancer | 85 | 5 | 0.65 | 7.69 | 0.0005 | 0.0023 | EE | |
LAMC3 | APAF1 | PTEN | PIK3R2 | |||||||||
05410 | Hypertrophic cardiomyopathy (HCM) | 83 | 5 | 0.64 | 7.87 | 0.0005 | 0.0023 | EE | |
ITGA5 | CACNA1D | CACNA1S | CACNA2D3 | |||||||||
04330 | Notch signaling pathway | 47 | 4 | 0.36 | 11.12 | 0.0005 | 0.0023 | - | |
NOTCH3 | DLL1 | PSEN1 | |||||||||
04530 | Tight junction | 132 | 6 | 1.01 | 5.94 | 0.0006 | 0.0026 | ID SCZ | |
MYH9 | MPDZ | CASK | PRKCA | PTEN | |||||||||
04310 | Wnt signaling pathway | 150 | 6 | 1.15 | 5.23 | 0.0011 | 0.0046 | - | |
TCF7L1 | ROCK1 | PRKCA | TBL1XR1 | PSEN1 | |||||||||
05146 | Amoebiasis | 106 | 5 | 0.81 | 6.16 | 0.0014 | 0.0057 | EE SCZ | |
GNAS | LAMC3 | PRKCA | PIK3R2 | |||||||||
04114 | Oocyte meiosis | 112 | 5 | 0.86 | 5.83 | 0.0018 | 0.0070 | ID | |
SMC3 | ADCY5 | SLK | RPS6KA3 | |||||||||
04115 | p53 signaling pathway | 68 | 4 | 0.52 | 7.69 | 0.0019 | 0.0071 | - | |
APAF1 | TSC2 | PTEN | |||||||||
04720 | Long-term potentiation | 70 | 4 | 0.54 | 7.47 | 0.0021 | 0.0075 | EE ID SCZ | |
PRKCA | RPS6KA3 | ITPR1 | |||||||||
04976 | Bile secretion | 71 | 4 | 0.54 | 7.36 | 0.0022 | 0.0076 | SCZ | |
GNAS | SLC4A2 | SLC5A1 | |||||||||
05016 | Huntington's disease | 183 | 6 | 1.40 | 4.28 | 0.0030 | 0.0100 | ID | |
DNAH2 | APAF1 | REST | SDHA | ITPR1 | |||||||||
05322 | Systemic lupus erythematosus | 136 | 5 | 1.04 | 4.80 | 0.0041 | 0.0128 | - | |
C3 | HIST1H2AE | H2AFV | TROVE2 | |||||||||
04960 | Aldosterone-regulated sodium reabsorption | 42 | 3 | 0.32 | 9.33 | 0.0041 | 0.0128 | - | |
PRKCA | NR3C2 | |||||||||
04914 | Progesterone-mediated oocyte maturation | 86 | 4 | 0.66 | 6.08 | 0.0044 | 0.0133 | SCZ | |
MAPK13 | ADCY5 | RPS6KA3 | |||||||||
05215 | Prostate cancer | 89 | 4 | 0.68 | 5.87 | 0.0049 | 0.0144 | EE ID | |
PDGFD | TCF7L1 | PTEN | |||||||||
04930 | Type II diabetes mellitus | 48 | 3 | 0.37 | 8.17 | 0.0060 | 0.0171 | EE | |
CACNA1D | CACNA1E | |||||||||
05213 | Endometrial cancer | 52 | 3 | 0.40 | 7.54 | 0.0074 | 0.0199 | - | |
TCF7L1 | PTEN | |||||||||
04916 | Melanogenesis | 101 | 4 | 0.77 | 5.18 | 0.0077 | 0.0199 | ID | |
GNAS | TCF7L1 | PRKCA | |||||||||
04150 | mTOR signaling pathway | 52 | 3 | 0.40 | 7.54 | 0.0074 | 0.0199 | - | |
TSC2 | RPS6KA3 | |||||||||
05014 | Amyotrophic lateral sclerosis (ALS) | 53 | 3 | 0.41 | 7.40 | 0.0078 | 0.0199 | EE ID | |
MAPK13 | APAF1 | |||||||||
05142 | Chagas disease (American trypanosomiasis) | 104 | 4 | 0.80 | 5.03 | 0.0085 | 0.0211 | - | |
GNAS | C3 | MAPK13 | |||||||||
05130 | Pathogenic Escherichia coli infection | 56 | 3 | 0.43 | 7.00 | 0.0091 | 0.0221 | ID | |
ROCK1 | TUBA1A | |||||||||
04660 | T cell receptor signaling pathway | 108 | 4 | 0.83 | 4.84 | 0.0097 | 0.0229 | - | |
PDCD1 | MAPK13 | PAK2 | |||||||||
05131 | Shigellosis | 61 | 3 | 0.47 | 6.43 | 0.0115 | 0.0266 | - | |
ITGA5 | MAPK13 | |||||||||
04670 | Leukocyte transendothelial migration | 116 | 4 | 0.89 | 4.51 | 0.0123 | 0.0277 | SCZ | |
MAPK13 | ROCK1 | PRKCA | |||||||||
05200 | Pathways in cancer | 326 | 7 | 2.49 | 2.81 | 0.0133 | 0.0293 | SCZ | |
LAMC3 | STK36 | TCF7L1 | PRKCA | PTEN | PIK3R2 | |||||||||
05214 | Glioma | 65 | 3 | 0.50 | 6.03 | 0.0137 | 0.0295 | EE ID | |
PRKCA | PTEN | |||||||||
04320 | Dorso-ventral axis formation | 24 | 2 | 0.18 | 10.89 | 0.0144 | 0.0297 | - | |
NOTCH3 | |||||||||
01100 | Metabolic pathways | 1130 | 16 | 8.65 | 1.85 | 0.0143 | 0.0297 | ID SCZ | |
SUCLA2 | CAD | ACACB | DNMT3A | AMY2B | PLCD4 | DGKA | SCP2 | WBSCR17 | PAFAH1B2 | ASAH2 | ST3GAL6 | SDHA | CYP4F3 | ST3GAL3 | |||||||||
00601 | Glycosphingolipid biosynthesis - lacto and neolacto series | 26 | 2 | 0.20 | 10.05 | 0.0168 | 0.0323 | - | |
ST3GAL6 | |||||||||
03018 | RNA degradation | 71 | 3 | 0.54 | 5.52 | 0.0173 | 0.0323 | - | |
CNOT6 | CNOT4 | |||||||||
04722 | Neurotrophin signaling pathway | 127 | 4 | 0.97 | 4.12 | 0.0167 | 0.0323 | ID | |
MAPK13 | PSEN1 | RPS6KA3 | |||||||||
04730 | Long-term depression | 70 | 3 | 0.54 | 5.60 | 0.0167 | 0.0323 | EE SCZ | |
GNAS | PRKCA | |||||||||
05218 | Melanoma | 71 | 3 | 0.54 | 5.52 | 0.0173 | 0.0323 | - | |
PDGFD | PTEN | |||||||||
05145 | Toxoplasmosis | 132 | 4 | 1.01 | 3.96 | 0.0189 | 0.0340 | SCZ | |
LAMC3 | MAPK13 | PIK3R2 | |||||||||
04080 | Neuroactive ligand-receptor interaction | 272 | 6 | 2.08 | 2.88 | 0.0189 | 0.0340 | EE ID | |
OPRL1 | GABRB3 | GRM7 | CHRM3 | HRH2 | |||||||||
04514 | Cell adhesion molecules (CAMs) | 133 | 4 | 1.02 | 3.93 | 0.0194 | 0.0342 | SCZ | |
PDCD1 | NRXN1 | NRXN2 | |||||||||
04370 | VEGF signaling pathway | 76 | 3 | 0.58 | 5.16 | 0.0207 | 0.0359 | - | |
MAPK13 | PRKCA | |||||||||
04260 | Cardiac muscle contraction | 77 | 3 | 0.59 | 5.09 | 0.0214 | 0.0364 | EE | |
CACNA1D | CACNA1S | |||||||||
00020 | Citrate cycle (TCA cycle) | 30 | 2 | 0.23 | 8.71 | 0.0221 | 0.0370 | - | |
SUCLA2 | |||||||||
04664 | Fc epsilon RI signaling pathway | 79 | 3 | 0.60 | 4.96 | 0.0229 | 0.0376 | - | |
MAPK13 | PRKCA | |||||||||
00640 | Propanoate metabolism | 32 | 2 | 0.24 | 8.17 | 0.0249 | 0.0403 | - | |
SUCLA2 | |||||||||
04350 | TGF-beta signaling pathway | 84 | 3 | 0.64 | 4.67 | 0.0268 | 0.0426 | ID | |
LTBP1 | THBS3 | |||||||||
04012 | ErbB signaling pathway | 87 | 3 | 0.67 | 4.51 | 0.0294 | 0.0460 | - | |
PRKCA | PAK2 | |||||||||
00565 | Ether lipid metabolism | 36 | 2 | 0.28 | 7.26 | 0.0310 | 0.0477 | - | |
PAFAH1B2 | ENPP2 |
KEGG accession | KEGG pathway name | Number of reference genes | Number of genes | Expected number | Ratio of entrichment | Raw P_Value | Adjusted P_Value | Genes related | Other disease |
---|---|---|---|---|---|---|---|---|---|
04720 | Long-term potentiation | 70 | 4 | 0.17 | 23.25 | 2.79e-05 | 0.0008 | EE ASD SCZ | |
GRIA1 | GRIN2A | CAMK2G | |||||||||
04110 | Cell cycle | 124 | 4 | 0.30 | 13.12 | 0.0003 | 0.0022 | - | |
RB1 | STAG1 | RBL2 | |||||||||
05014 | Amyotrophic lateral sclerosis (ALS) | 53 | 3 | 0.13 | 23.03 | 0.0003 | 0.0022 | EE ASD | |
GRIA1 | GRIN2A | |||||||||
04722 | Neurotrophin signaling pathway | 127 | 4 | 0.31 | 12.81 | 0.0003 | 0.0022 | ASD | |
RAPGEF1 | NGFR | CAMK2G | |||||||||
05010 | Alzheimer's disease | 167 | 4 | 0.41 | 9.75 | 0.0008 | 0.0048 | ASD | |
GRIN2A | NDUFA10 | GRIN2B | |||||||||
04530 | Tight junction | 132 | 3 | 0.32 | 9.25 | 0.0043 | 0.0215 | ASD SCZ | |
MYH9 | CTNNB1 | |||||||||
00510 | N-Glycan biosynthesis | 49 | 2 | 0.12 | 16.61 | 0.0065 | 0.0255 | - | |
TUSC3 | |||||||||
00561 | Glycerolipid metabolism | 50 | 2 | 0.12 | 16.27 | 0.0068 | 0.0255 | - | |
DGKH | |||||||||
05130 | Pathogenic Escherichia coli infection | 56 | 2 | 0.14 | 14.53 | 0.0085 | 0.0283 | ASD | |
TUBA1A | |||||||||
05016 | Huntington's disease | 183 | 3 | 0.45 | 6.67 | 0.0105 | 0.0307 | ASD | |
DLG4 | NDUFA10 | |||||||||
05214 | Glioma | 65 | 2 | 0.16 | 12.52 | 0.0113 | 0.0307 | EE ASD | |
RB1 | |||||||||
05211 | Renal cell carcinoma | 70 | 2 | 0.17 | 11.62 | 0.0130 | 0.0307 | - | |
RAPGEF1 | |||||||||
04622 | RIG-I-like receptor signaling pathway | 71 | 2 | 0.17 | 11.46 | 0.0133 | 0.0307 | - | |
DDX3X | |||||||||
05412 | Arrhythmogenic right ventricular cardiomyopathy (ARVC) | 74 | 2 | 0.18 | 11.00 | 0.0144 | 0.0309 | ASD SCZ | |
CTNNB1 | |||||||||
04350 | TGF-beta signaling pathway | 84 | 2 | 0.21 | 9.69 | 0.0183 | 0.0366 | ASD | |
SMAD6 | |||||||||
05215 | Prostate cancer | 89 | 2 | 0.22 | 9.14 | 0.0204 | 0.0382 | EE ASD | |
RB1 | |||||||||
01100 | Metabolic pathways | 1130 | 7 | 2.78 | 2.52 | 0.0217 | 0.0383 | ASD SCZ | |
DGKH | MAT1A | TUSC3 | PNLIPRP1 | GFPT2 | MGAT5B | |||||||||
04912 | GnRH signaling pathway | 101 | 2 | 0.25 | 8.06 | 0.0258 | 0.0407 | ASD SCZ | |
CAMK2G | |||||||||
04916 | Melanogenesis | 101 | 2 | 0.25 | 8.06 | 0.0258 | 0.0407 | ASD | |
CTNNB1 | |||||||||
04080 | Neuroactive ligand-receptor interaction | 272 | 3 | 0.67 | 4.49 | 0.0298 | 0.0446 | EE ASD | |
GRIA1 | GRIN2A | |||||||||
04114 | Oocyte meiosis | 112 | 2 | 0.28 | 7.27 | 0.0312 | 0.0446 | ASD | |
CAMK2G | SMC1A |
KEGG accession | KEGG pathway name | Number of reference genes | Number of genes | Expected number | Ratio of entrichment | Raw P_Value | Adjusted P_Value | Genes related | Other disease |
---|---|---|---|---|---|---|---|---|---|
04080 | Neuroactive ligand-receptor interaction | 272 | 7 | 0.69 | 10.18 | 6.33e-06 | 0.0002 | ID ASD | |
GABRA1 | GABRB1 | GABRB3 | RXFP1 | TAAR2 | GRIN2B | |||||||||
05014 | Amyotrophic lateral sclerosis (ALS) | 53 | 3 | 0.13 | 22.40 | 0.0003 | 0.0026 | ID ASD | |
GRIN2B | GRIN1 | |||||||||
04144 | Endocytosis | 201 | 5 | 0.51 | 9.84 | 0.0002 | 0.0026 | SCZ | |
VPS37A | IQSEC2 | SMURF1 | RAB5C | |||||||||
04020 | Calcium signaling pathway | 177 | 4 | 0.45 | 8.94 | 0.0011 | 0.0062 | ASD SCZ | |
RYR2 | ATP2B4 | CACNA1A | |||||||||
05410 | Hypertrophic cardiomyopathy (HCM) | 83 | 3 | 0.21 | 14.30 | 0.0012 | 0.0062 | ASD | |
RYR2 | TTN | |||||||||
05414 | Dilated cardiomyopathy | 90 | 3 | 0.23 | 13.19 | 0.0016 | 0.0069 | ASD SCZ | |
RYR2 | TTN | |||||||||
04930 | Type II diabetes mellitus | 48 | 2 | 0.12 | 16.49 | 0.0066 | 0.0245 | ASD | |
MTOR | |||||||||
04742 | Taste transduction | 52 | 2 | 0.13 | 15.22 | 0.0077 | 0.0250 | - | |
KCNB1 | |||||||||
04730 | Long-term depression | 70 | 2 | 0.18 | 11.30 | 0.0137 | 0.0312 | ASD SCZ | |
GNAO1 | |||||||||
04510 | Focal adhesion | 200 | 3 | 0.51 | 5.93 | 0.0144 | 0.0312 | ASD SCZ | |
FLNA | PTEN | |||||||||
04720 | Long-term potentiation | 70 | 2 | 0.18 | 11.30 | 0.0137 | 0.0312 | ID ASD SCZ | |
GRIN2B | |||||||||
05214 | Glioma | 65 | 2 | 0.16 | 12.17 | 0.0119 | 0.0312 | ID ASD | |
PTEN | |||||||||
04260 | Cardiac muscle contraction | 77 | 2 | 0.19 | 10.28 | 0.0164 | 0.0328 | ASD | |
RYR2 | |||||||||
05222 | Small cell lung cancer | 85 | 2 | 0.21 | 9.31 | 0.0197 | 0.0349 | ASD | |
PTEN | |||||||||
05215 | Prostate cancer | 89 | 2 | 0.22 | 8.89 | 0.0215 | 0.0349 | ID ASD | |
PTEN | |||||||||
04970 | Salivary secretion | 89 | 2 | 0.22 | 8.89 | 0.0215 | 0.0349 | ASD SCZ | |
BEST2 | |||||||||
04972 | Pancreatic secretion | 101 | 2 | 0.26 | 7.83 | 0.0272 | 0.0416 | ASD | |
RYR2 | |||||||||
05146 | Amoebiasis | 106 | 2 | 0.27 | 7.47 | 0.0297 | 0.0429 | ASD SCZ | |
RAB5C | COL4A4 |
KEGG accession | KEGG pathway name | Number of reference genes | Number of genes | Expected number | Ratio of entrichment | Raw P_Value | Adjusted P_Value | Genes related | Other disease |
---|---|---|---|---|---|---|---|---|---|
04020 | Calcium signaling pathway | 177 | 10 | 1.14 | 8.76 | 2.63e-07 | 1.81e-05 | ASD EE | |
ITPR1 | RYR3 | ADCY9 | PTK2B | CAMK4 | GRIN2A | HTR2A | CACNA1I | NOS3 | |||||||||
05416 | Viral myocarditis | 70 | 6 | 0.45 | 13.30 | 6.31e-06 | 0.0002 | - | |
MYH9 | LAMA2 | MYH10 | MYH7B | ICAM1 | |||||||||
04270 | Vascular smooth muscle contraction | 116 | 6 | 0.75 | 8.02 | 0.0001 | 0.0017 | ASD | |
ACTA2 | KCNU1 | ITPR1 | ADCY9 | MYH11 | |||||||||
04670 | Leukocyte transendothelial migration | 116 | 6 | 0.75 | 8.02 | 0.0001 | 0.0017 | ASD | |
PTK2B | RASSF5 | ACTN1 | ESAM | ICAM1 | |||||||||
04530 | Tight junction | 132 | 6 | 0.85 | 7.05 | 0.0002 | 0.0028 | ID ASD | |
MYH9 | ACTN1 | MYH10 | MYH7B | CTNNA2 | |||||||||
01100 | Metabolic pathways | 1130 | 18 | 7.28 | 2.47 | 0.0004 | 0.0034 | ID ASD | |
PRDX6 | DPM1 | BCAT1 | CHSY1 | ST3GAL6 | FLAD1 | GLS | LCT | AOX1 | ALAS1 | SQLE | PIK3C2B | DPYD | ACSL4 | STT3B | DNMT1 | NOS3 | |||||||||
05200 | Pathways in cancer | 326 | 9 | 2.10 | 4.28 | 0.0003 | 0.0034 | ASD | |
RASSF5 | MAPK8 | TPR | HSP90AA1 | GLI3 | LAMA2 | HIF1A | CTNNA2 | |||||||||
04144 | Endocytosis | 201 | 7 | 1.30 | 5.40 | 0.0004 | 0.0034 | EE | |
CHMP2A | ASAP2 | CLTCL1 | ASAP1 | HSPA8 | PML | |||||||||
04912 | GnRH signaling pathway | 101 | 5 | 0.65 | 7.68 | 0.0005 | 0.0038 | ID ASD | |
PTK2B | MAPK8 | ITPR1 | ADCY9 | |||||||||
04141 | Protein processing in endoplasmic reticulum | 165 | 6 | 1.06 | 5.64 | 0.0007 | 0.0048 | - | |
MAPK8 | STT3B | HSP90AA1 | MBTPS1 | UBQLN1 | |||||||||
04540 | Gap junction | 90 | 4 | 0.58 | 6.89 | 0.0028 | 0.0114 | ASD | |
HTR2A | ITPR1 | ADCY9 | |||||||||
04510 | Focal adhesion | 200 | 6 | 1.29 | 4.65 | 0.0020 | 0.0114 | ASD EE | |
MAPK8 | RELN | ACTN1 | LAMA2 | COL6A2 | |||||||||
04810 | Regulation of actin cytoskeleton | 213 | 6 | 1.37 | 4.37 | 0.0027 | 0.0114 | ASD | |
MYH9 | SSH2 | ACTN1 | CD14 | MYH10 | |||||||||
04970 | Salivary secretion | 89 | 4 | 0.57 | 6.97 | 0.0027 | 0.0114 | ASD EE | |
ITPR1 | RYR3 | ADCY9 | |||||||||
04512 | ECM-receptor interaction | 85 | 4 | 0.55 | 7.30 | 0.0023 | 0.0114 | ASD | |
RELN | LAMA2 | COL6A2 | |||||||||
04914 | Progesterone-mediated oocyte maturation | 86 | 4 | 0.55 | 7.22 | 0.0024 | 0.0114 | ASD | |
MAPK8 | HSP90AA1 | ADCY9 | |||||||||
04120 | Ubiquitin mediated proteolysis | 135 | 5 | 0.87 | 5.75 | 0.0019 | 0.0114 | - | |
BIRC6 | HUWE1 | UBR5 | PML | |||||||||
00770 | Pantothenate and CoA biosynthesis | 16 | 2 | 0.10 | 19.39 | 0.0047 | 0.0180 | - | |
BCAT1 | |||||||||
05146 | Amoebiasis | 106 | 4 | 0.68 | 5.85 | 0.0050 | 0.0182 | ASD EE | |
ACTN1 | LAMA2 | CD14 | |||||||||
00360 | Phenylalanine metabolism | 17 | 2 | 0.11 | 18.25 | 0.0053 | 0.0183 | - | |
MIF | |||||||||
04621 | NOD-like receptor signaling pathway | 58 | 3 | 0.37 | 8.02 | 0.0063 | 0.0207 | - | |
MAPK8 | HSP90AA1 | |||||||||
04514 | Cell adhesion molecules (CAMs) | 133 | 4 | 0.86 | 4.67 | 0.0110 | 0.0292 | ASD | |
ESAM | NFASC | NRXN1 | |||||||||
04730 | Long-term depression | 70 | 3 | 0.45 | 6.65 | 0.0106 | 0.0292 | ASD EE | |
GNAO1 | GRID2 | |||||||||
05145 | Toxoplasmosis | 132 | 4 | 0.85 | 4.70 | 0.0107 | 0.0292 | ASD | |
MAPK8 | LAMA2 | GNAO1 | |||||||||
04976 | Bile secretion | 71 | 3 | 0.46 | 6.55 | 0.0110 | 0.0292 | ASD | |
ADCY9 | HMGCR | |||||||||
04720 | Long-term potentiation | 70 | 3 | 0.45 | 6.65 | 0.0106 | 0.0292 | ID ASD EE | |
CAMK4 | GRIN2A | |||||||||
05412 | Arrhythmogenic right ventricular cardiomyopathy (ARVC) | 74 | 3 | 0.48 | 6.29 | 0.0123 | 0.0303 | ID ASD | |
ACTN1 | LAMA2 | |||||||||
04971 | Gastric acid secretion | 74 | 3 | 0.48 | 6.29 | 0.0123 | 0.0303 | ASD | |
ITPR1 | ADCY9 | |||||||||
05414 | Dilated cardiomyopathy | 90 | 3 | 0.58 | 5.17 | 0.0206 | 0.0490 | ASD EE | |
LAMA2 | ADCY9 | |||||||||
05340 | Primary immunodeficiency | 35 | 2 | 0.23 | 8.86 | 0.0214 | 0.0492 | - | |
TNFRSF13C | BLNK |
Copyright © 2014 Beijing Institutes of Life Science, Chinese Academy of Sciences & Institute of Genomic Medicine, Wenzhou Medical University